Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
BOSTON, March 22, 2017 -- Block & Leviton LLP (www.blockesq.com), a Boston-based securities litigation firm representing investors nationwide, reminds investors of PixarBio Corporation (“PixarBio” or the “Company”) (OTCMKTS:PXRB) of the March 27, 2017 lead plaintiff deadline.
If you purchased PixarBio securities in either the Company’s private placement, or on the open market between October 31, 2016 and January 20, 2017, you are encouraged to contact attorney Bradley Vettraino at (617) 398-5600, by email at [email protected], or by visiting www.blockesq.com/pixarbio.
On January 3, 2017, PixarBio's CEO announced a purported attempt by the Company to acquire InVivo Therapeutics Holdings Corp. ("InVivo") in a $100 million takeover bid. InVivo refuted PixarBio’s purported offer as "not credible." On January 23, 2017, the SEC announced that it had halted trading in the securities of PixarBio, citing concerns about possible "manipulative or deceptive activities" in the market for the Company's stock.
PixarBio’s stock plunged more than 35% during the month of January, causing tens of millions in losses to investors.
The lawsuit subsequently filed by Block & Leviton against PixarBio and its CEO, in the United States District Court for Massachusetts alleges that Defendants failed to disclose and/or made false and/or misleading statements regarding: (1) the company’s business combinations and current shareholders; (2) the identity and qualifications of key shareholders and employees; (3) the company’s current and prospective development efforts, and (4) that, as a result, the Company’s business, operations, and prospects, were false and misleading.
As a member of the class, you may seek to file a motion to serve as a lead plaintiff or take no action and remain an absent class member. Confidentiality to whistleblowers or others with information relevant to the lawsuit is assured.
Block & Leviton LLP is a Boston-based law firm representing investors nationwide. The firm's lawyers have collectively been prosecuting securities cases on behalf of individual and institutional investors for over 50 years, and have recovered billions of dollars on their behalf. Block & Leviton's investigations into corporate wrongdoing were recently covered by the New York Times.
This notice may constitute attorney advertising.
CONTACT: Block & Leviton LLP Bradley J. Vettraino 155 Federal Street, Suite 400 Boston, MA 02110 (617) 398-5600 [email protected]
